PDCD1 and non-small cell lung carcinoma: Avelumab (MSB0010718c, anti-PD-L1 IgG1) is a novel mAb that is used to inhibit the interaction between PD-1 and PD-L1, and phase I and II clinical trials highlight that it is well tolerated and show its prognostic response in Merkel cell carcinoma (MCC), NSCLC, and urothelial carcinoma (24–27).